SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Cardiovasc Diabetol. 2025;24(1):41.

Proteinuria and the risk of Incident atrial fibrillation according to glycemic stages: a nationwide population-based cohort study.

, , , , , , , , , ,

제1저자 여무한, 이소령 · 교신저자 최의근, 한경도

소속 (9)
  1. Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, Republic of Korea.
  2. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  3. Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, Republic of Korea. choiek17@snu.ac.kr.
  4. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. choiek17@snu.ac.kr.
  5. Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea.
  6. Statistics and Actuarial Science, Soongsil University, 369 Sangdo-ro, Dongjak-gu, Seoul, Republic of Korea.
  7. Statistics and Actuarial Science, Soongsil University, 369 Sangdo-ro, Dongjak-gu, Seoul, Republic of Korea. hkd@ssu.ac.kr.
  8. Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Chest and Heart Hospital, Liverpool, UK.
  9. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Abstract

BACKGROUND Diabetes mellitus (DM) and proteinuria each independently raise the risk of atrial fibrillation (AF). We aimed to investigate the relationship between proteinuria and the risk of incident AF across glycemic stages.

METHODS A cohort of 4,044,524 individuals without prior AF and type 1 DM was selected from the 2009 Korean National Health Insurance Service health checkup data. The individuals were categorized into five glycemic stages: normal, prediabetes, new-onset DM, early DM (< 5 years), and late DM (≥ 5 years). Proteinuria was graded using a urine dipstick test. The development of incident AF was tracked until 2023.

RESULTS Overall, the cohort (mean age 47 ± 14 years, 44.8% female) showed increasing annual AF incidence rates from 2.05 to 7.22 per 1000 person-years from normal to late DM (p < 0.001). Incidence rates increased from 2.46 to 8.18 per 1000 person-years with increasing proteinuria (p < 0.001). Adjusted Cox regression models revealed a heightened AF risk with higher proteinuria across all glycemic stages (adjusted hazard ratios for urine dipstick 3+/4+: 1.58, 1.64, 2.39, 2.12, and 2.53 for normal, prediabetes, new-onset DM, early DM, and late DM, respectively). The proteinuria-AF association was more pronounced in individuals with DM than in those without DM but was similar among the new-onset and established DM groups.

CONCLUSIONS Proteinuria is an independent and significant risk factor for incident AF at all glycemic stages. The risk of incident AF in patients with DM can be stratified by measuring the level of proteinuria rather than comparing the duration of DM. Tailoring clinical strategies to proteinuria level could potentially mitigate this risk, improving patient outcomes.

© 2025. The Author(s).

Keywords

Atrial fibrillationDiabetes MellitusProteinuria

Figures

Fig. 1
Fig. 1 Study population and design. T1DM: type 1 diabetes mellitus; AF: atrial fibrillation; DM: diabetes mellitus
Fig. 2
Fig. 2 Kaplan-Meier curves for AF incidence corresponding to glycemic stages and proteinuria level. DM: diabetes mellitus; Prediabetes: impaired fasting glucose (fasting glucose level from 100 to 126 mg/dL); New-onset DM: DM first diagnosed at the time of screening; Early DM: DM duration after diagnosis < 5 years; Late DM: DM duration after diagnosis ≥ 5 years
Fig. 3
Fig. 3 AF incidence rates and hazard ratios in Cox Proportional-Hazards Regression Model 4. DM: diabetes mellitus; Prediabetes: impaired fasting glucose (fasting glucose level from 100 to 126 mg/dL); New-onset DM: DM first diagnosed at the time of screening; Early DM: DM duration after diagnosis < 5 years; Late DM: DM duration after diagnosis ≥ 5 years

그림 출처: PubMed Central 공개 논문 (PMC11762047)

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study received an exemption from the IRB of Seoul National University Hospital (IRB no. 2408-098-1562). Informed consent was not obtained because the database was anonymized. The utilization of the NHID for 2009–2023 will be approved in 2024. Consent for publication: Not applicable. Competing interests: EKC: Research grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical Co., Daiichi-Sankyo, DeepQure, Dreamtech Co., Ltd., Jeil Pharmaceutical Co. Ltd, Medtronic, Samjinpharm, Samsung Electronics Co., Ltd., Seers Technology, and Skylabs. GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator.

그 밖의 정보
출판 형태
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't
저널
Cardiovascular diabetology · eISSN 1475-2840
전자 출판
2025-01-24
MeSH
Humans · Female · Proteinuria* / epidemiology / diagnosis / urine · Middle Aged · Male · Incidence · Atrial Fibrillation* / epidemiology / diagnosis · Republic of Korea / epidemiology · Risk Factors · Risk Assessment · Blood Glucose* / metabolism · Adult · Prediabetic State* / epidemiology / diagnosis / blood · Time Factors · Biomarkers / blood / urine · Aged · Diabetes Mellitus* / diagnosis / epidemiology / blood · Prognosis · Databases, Factual · Urinalysis
Substances
Blood Glucose · Biomarkers
연구비
Patient-Centered Clinical Research Coordinating Center (PACEN), Ministry of Health &amp; Welfare, Republic of Korea RS-2021-KH119931 · National Research Foundation of Korea IRIS RS-2024-00340590
참고문헌
27편